Biodesix (BDSX) CEO vests 611 RSUs; sells 189 shares at $7.62

Biodesix (BDSX) disclosed insider activity by its President & CEO and Director, Scott Hutton.

Accepted by SEC EDGAR 11/13/2025 - 04:53 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Biodesix (BDSX) disclosed insider activity by its President & CEO and Director, Scott Hutton. On 11/10/2025, 611 shares of Common Stock were acquired upon RSU vesting, followed by an automatic sale of 189 shares at $7.62 to cover taxes. Following these transactions, the reporting person directly beneficially owned 37,311 shares.

The amounts reflect the one-for-twenty reverse stock split effective September 15, 2025. After the vesting event, 610 RSUs remained outstanding, with RSUs vesting in successive quarterly installments measured from February 8, 2022.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Hutton Scott

Role President & CEO

Sold 189 shs ($1K)

Approx. gross sale proceeds $1K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	611	$0.00	$0.00
Exercise	Common Stock	611	$0.00	$0.00
Sale	Common Stock	189	$7.62	$1K

Holdings After Transaction: Restricted Stock Units — 610 contracts (Direct); Common Stock — 37,311 shares (Direct)

Footnotes (5)

1. F1. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").
2. F2. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. Includes 448 shares of the Issuer's Common Stock, as adjusted for the Reverse Stock Split, purchased under the Issuer's Employee Stock Purchase Plan on September 2, 2025.
4. F4. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
5. F5. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biodesix (BDSX) disclose in this Form 4?

The CEO and Director reported RSU vesting of 611 shares and an automatic sale of 189 shares at $7.62 for taxes on 11/10/2025.

How many Biodesix (BDSX) shares does the insider own after the transactions?

Direct beneficial ownership is 37,311 shares following the reported transactions.

What price were the sold shares transacted at?

The 189 shares were sold at $7.62 per share to cover taxes upon RSU vesting.

How many RSUs remain outstanding after the vesting?

There are 610 RSUs remaining outstanding after the 611-share vesting.

Did a reverse stock split affect the reported numbers for BDSX?

Yes. All numbers reflect the one-for-twenty reverse stock split effective September 15, 2025.

What is the insider’s role at Biodesix (BDSX)?

The reporting person is President & CEO and a Director of Biodesix.

How do the RSUs vest for Biodesix’s insider?

RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hutton Scott

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		M		611(1)	A	(2)	37,500(1)(3)	D
Common Stock	11/10/2025		S(4)		189	D	$7.62	37,311	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	11/10/2025		M			611(1)	(5)	(5)	Common Stock	611(1)	$0	610(1)	D

Explanation of Responses:

1. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").

2. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

3. Includes 448 shares of the Issuer's Common Stock, as adjusted for the Reverse Stock Split, purchased under the Issuer's Employee Stock Purchase Plan on September 2, 2025.

4. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

5. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Scott Hutton	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.